For help on how to get the results you want, see our search tips.
1646 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Opinions on maximum residue limits Remove Opinions on maximum residue limits filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Juluca (updated)
dolutegravir sodium, rilpivirine hydrochloride, HIV Infections
Date of authorisation: 16/05/2018, Revision: 14, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Cosentyx (updated)
Secukinumab, Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing
Date of authorisation: 14/01/2015, Revision: 28, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Tesavel (updated)
sitagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 10/01/2008, Revision: 27, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Pluvicto (updated)
lutetium (177Lu) vipivotide tetraxetan, Prostatic Neoplasms, Castration-Resistant
Date of authorisation: 09/12/2022,
, Revision: 1, Authorised, Last updated: 02/02/2023
-
List item
Human medicine European public assessment report (EPAR): ellaOne (updated)
ulipristal, Contraception, Postcoital
Date of authorisation: 15/05/2009, Revision: 27, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Helicobacter Test INFAI (updated)
urea (13C), Breath Tests; Helicobacter Infections
Date of authorisation: 14/08/1997, Revision: 20, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Prometax (updated)
rivastigmine, Alzheimer Disease; Parkinson Disease; Dementia
Date of authorisation: 03/12/1998, Revision: 44, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Siklos (updated)
hydroxycarbamide, Anemia, Sickle Cell
Date of authorisation: 29/06/2007, Revision: 23, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Exelon (updated)
rivastigmine, Dementia; Alzheimer Disease; Parkinson Disease
Date of authorisation: 11/05/1998, Revision: 45, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Caprelsa (updated)
Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012,
, Revision: 23, Authorised, Last updated: 01/02/2023
-
List item
Human medicine European public assessment report (EPAR): Xolair (updated)
omalizumab, Asthma; Urticaria
Date of authorisation: 25/10/2005, Revision: 44, Authorised, Last updated: 01/02/2023 -
List item
Human medicine European public assessment report (EPAR): Ninlaro (updated)
ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016,, 
, , Revision: 15, Authorised, Last updated: 01/02/2023
-
List item
Human medicine European public assessment report (EPAR): Ogluo (updated)
Glucagon, Diabetes Mellitus
Date of authorisation: 11/02/2021, Revision: 4, Authorised, Last updated: 01/02/2023 -
List item
Human medicine European public assessment report (EPAR): Plavix (updated)
clopidogrel hydrogen sulfate, Stroke; Peripheral Vascular Diseases; Atrial Fibrillation; Myocardial Infarction; Acute Coronary Syndrome
Date of authorisation: 15/07/1998, Revision: 47, Authorised, Last updated: 31/01/2023 -
List item
Human medicine European public assessment report (EPAR): Mayzent (updated)
Siponimod fumaric acid, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 13/01/2020,, Revision: 9, Authorised, Last updated: 31/01/2023
-
List item
Human medicine European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma) (updated)
Lonapegsomatropin, Growth and Development
Date of authorisation: 11/01/2022,, , Revision: 3, Authorised, Last updated: 31/01/2023
-
List item
Human medicine European public assessment report (EPAR): Celdoxome pegylated liposomal (updated)
doxorubicin hydrochloride, Breast Neoplasms; Ovarian Neoplasms; Multiple Myeloma; Sarcoma, Kaposi
Date of authorisation: 15/09/2022, Authorised, Last updated: 31/01/2023 -
List item
Human medicine European public assessment report (EPAR): Efficib (updated)
sitagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 15/07/2008, Revision: 32, Authorised, Last updated: 31/01/2023 -
List item
Human medicine European public assessment report (EPAR): Truxima (updated)
rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Wegener Granulomatosis; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopic Polyangiitis
Date of authorisation: 17/02/2017,
, Revision: 19, Authorised, Last updated: 31/01/2023
-
List item
Human medicine European public assessment report (EPAR): Xelevia (updated)
sitagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 21/03/2007, Revision: 37, Authorised, Last updated: 31/01/2023 -
List item
Human medicine European public assessment report (EPAR): Ceplene (updated)
Histamine dihydrochloride, Leukemia, Myeloid, Acute
Date of authorisation: 07/10/2008,, 
, Revision: 12, Authorised, Last updated: 30/01/2023
-
List item
Human medicine European public assessment report (EPAR): Liprolog (updated)
insulin lispro, Diabetes Mellitus
Date of authorisation: 01/08/2001, Revision: 30, Authorised, Last updated: 30/01/2023 -
List item
Human medicine European public assessment report (EPAR): Jylamvo (updated)
Methotrexate, Arthritis, Psoriatic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis; Arthritis, Rheumatoid; Arthritis
Date of authorisation: 29/03/2017, Revision: 11, Authorised, Last updated: 30/01/2023 -
List item
Human medicine European public assessment report (EPAR): Tecartus (updated)
Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel), Lymphoma, Mantle-Cell
Date of authorisation: 14/12/2020,, , , Revision: 4, Authorised, Last updated: 30/01/2023
-
List item
Human medicine European public assessment report (EPAR): Qdenga (updated)
Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated, Dengue virus, serotype 2, live, attenuated, Dengue
Date of authorisation: 05/12/2022,, Authorised, Last updated: 30/01/2023